Faruqi & Faruqi Reminds LifeMD Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 27, 2025 - LFMD

Core Viewpoint - The complaint against LifeMD alleges that the company and its executives violated federal securities laws by making misleading statements and failing to disclose critical information regarding their competitive position and customer acquisition costs [2]. Financial Performance - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from the previous guidance of $268 to $275 million [3]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [3]. Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4]. - The law firm Faruqi & Faruqi encourages individuals with information regarding LifeMD's conduct to come forward, including whistleblowers and former employees [5].